Filing summary
Entity and period: The supplied filing is Mast Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 14, 2016. It is not a Savara Inc. filing, despite the request metadata. The filing reports annual results and unaudited quarterly results, including the quarter ended December 31, 2015.
Business context
Mast was a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead candidate, vepoloxamer, was in Phase 3 development for sickle cell vaso-occlusive crisis and Phase 2 development for chronic heart failure with reduced ejection fraction (HFrEF). AIR001, an inhaled sodium nitrite solution, was in Phase 2 development for heart failure with preserved ejection fraction (HFpEF).
Financial results and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $28.3 million | $19.4 million |
| Selling, general and administrative expense | $11.0 million | $9.5 million |
| Operating loss | $39.4 million | $29.3 million |
| Net loss | $39.8 million | $28.7 million |
| Basic and diluted loss per share | $0.25 | $0.23 |
| Net cash used in operating activities | $32.9 million | $24.6 million |
For Q4 2015, revenue was $0; operating loss was $9.7 million and net loss was $10.2 million, or $0.06 per share. Q4 2014 operating loss was $7.4 million and net loss was $7.3 million, or $0.05 per share.
At December 31, 2015, cash and cash equivalents were $23.1 million and investment securities were $17.9 million, for combined liquidity of $41.0 million. Working capital was $19.1 million; total assets were $54.2 million, total liabilities $30.3 million, and stockholders’ equity $23.9 million. The company had borrowed $15 million under a Hercules debt facility; the balance-sheet carrying value was approximately $14.7 million, including current and long-term portions. Interest was 9.20% at year-end. No profit or operating margin was reported; the company had no product revenue.
Cash declined by $12.8 million during 2015. Financing provided $16.8 million, mainly from $14.8 million net debt proceeds and $2.0 million net ATM equity proceeds; investing activities provided $3.4 million.
Changes versus prior period
- Annual operating expenses rose to $39.4 million from $29.3 million, driven mainly by higher R&D spending. R&D increased 45.4%, reflecting EPIC trial costs, vepoloxamer manufacturing and toxicology, and the start of the HFrEF Phase 2 program.
- Net loss widened by $11.1 million. Loss per share increased from $0.23 to $0.25, while weighted-average shares rose from 122.4 million to 162.2 million.
- Operating cash use increased by $8.3 million. Cash and investments fell from $57.3 million at year-end 2014 to $41.0 million at year-end 2015.
- The company raised $15 million through Hercules debt in 2015, whereas 2014 financing had included a $21 million public offering and ATM sales.
Outlook, commentary, and key risks
- EPIC enrolled 388 patients by February 2016; top-line results were expected in Q2 2016. The filing states that results were not yet available. Prior Phase 3 study C97-1248 missed statistical significance on its primary endpoint in the overall population, though post hoc analyses reported stronger effects in certain subgroups.
- Subject to positive EPIC results and FDA discussions, management planned a rolling NDA submission beginning in Q4 2016, completion in Q1 2017, and a potential U.S. launch by year-end 2017. These were plans, not assured outcomes.
- Management projected 2016 operating expenses of $38–$43 million, excluding share-based compensation, if EPIC results supported an NDA. It expected to raise additional capital before Q4 2016. If funding were unavailable or EPIC results were negative, it planned to reduce operations; the filing estimated reduced-scope resources could last into Q1 2017.
- The Hercules facility required a $10 million prepayment on July 31, 2016 unless the company demonstrated positive EPIC results to Hercules’ reasonable satisfaction. The filing also describes a possible principal payment beginning July 2016, subject to the study-result conditions. Debt was secured by substantially all assets other than intellectual property, but included proceeds from IP dispositions; covenants and default provisions could constrain financing and operations.
- The independent auditor’s report included an emphasis-of-matter paragraph concerning liquidity. The company had recurring losses, no operating revenue, and depended on additional financing to fund planned operations; management cautioned that financing might not be available on acceptable terms or at all.
- In February 2016, after year-end, Mast raised $8.0 million gross (approximately $7.3 million net) in an offering of shares and warrants. The same month it reported positive top-line results from a 30-patient AIR001 Phase 2a HFpEF study: the primary exercise-related pulmonary capillary wedge pressure endpoint was statistically significant versus control. Further study was ongoing or planned.
- Material risks included clinical failure or requests for additional trials, regulatory and manufacturing delays, reliance on single-source suppliers, competing therapies, reimbursement and commercialization uncertainty, potential dilution, debt repayment/default risk, and continued listing compliance. Management reported effective disclosure controls and internal control over financial reporting; the auditor also opined that internal controls were effective.
Important facts for investors to verify
- Confirm the issuer identity: this is Mast Therapeutics, Inc., not Savara Inc.; verify the intended company and filing before relying on the summary.
- Review subsequent filings for EPIC results, FDA feedback, and whether the planned NDA timeline or clinical program changed.
- Verify current cash, burn rate, financing proceeds, debt balance, repayment conditions, and any covenant amendments; the liquidity figures here are as of December 31, 2015, with a February 2016 offering disclosed as a subsequent event.
- Assess whether AIR001’s preliminary Phase 2a result was confirmed in larger studies and whether the HFrEF and HFpEF programs advanced.
- Review the full audited financial statements, debt agreement, risk factors, and later disclosures for developments not captured in this 2015 annual report.